Teva Pharmaceutical Industries (TEVA) Other Non-Current Liabilities (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Other Non-Current Liabilities across 18 years of filings, most recently posting $3.7 billion for Q1 2026.

• Quarterly Other Non-Current Liabilities fell 7.53% year-over-year to $3.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 billion (down 7.53% YoY) and the FY2025 annual result came in at $3.8 billion, down 5.46% from the prior year.
• Other Non-Current Liabilities eased to $3.7 billion in Q1 2026, from $3.8 billion in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $4.4 billion in Q2 2024 and troughed at $3.3 billion in Q1 2022.
• A 5-year average of $3.9 billion and a median of $4.0 billion in 2023 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities jumped 75.17% — and 2025, when it declined 15.65%.
• Tracing TEVA's Other Non-Current Liabilities over 5 years: stood at $3.9 billion in 2022, then gained by 1.88% to $4.0 billion in 2023, then increased by 0.22% to $4.0 billion in 2024, then fell by 5.46% to $3.8 billion in 2025, then dropped by 2.6% to $3.7 billion in 2026.
• Business Quant data shows TEVA's Other Non-Current Liabilities at $3.7 billion in Q1 2026, $3.8 billion in Q4 2025, and $3.7 billion in Q3 2025.